Assessment of positive selection across SARS-CoV-2 variants via maximum likelihood.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
05
2023
accepted:
24
08
2023
medline:
18
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
Study of the genome of the SARS-CoV-2 virus, particularly with regard to understanding evolution of the virus, is crucial for managing the COVID-19 pandemic. To this end, we sample viral genomes from the GISAID repository and use several of the maximum likelihood approaches implemented in PAML, a collection of open source programs for phylogenetic analyses of DNA and protein sequences, to assess evidence for positive selection in the protein-coding regions of the SARS-CoV-2 genome. Across all major variants identified by June 2021, we find limited evidence for positive selection. In particular, we identify positive selection in a small proportion of sites (5-15%) in the protein-coding region of the spike protein across variants. Most other variants did not show a strong signal for positive selection overall, though there were indications of positive selection in the Delta and Kappa variants for the nucleocapsid protein. We additionally use a forward selection procedure to fit a model that allows branch-specific estimates of selection along a phylogeny relating the variants, and find that there is variation in the selective pressure across variants for the spike protein. Our results highlight the utility of computational approaches for identifying genomic regions under selection.
Identifiants
pubmed: 37708144
doi: 10.1371/journal.pone.0291271
pii: PONE-D-23-15023
pmc: PMC10501574
doi:
Substances chimiques
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291271Informations de copyright
Copyright: © 2023 Middleton, Kubatko. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Mol Biol Evol. 1994 Sep;11(5):725-36
pubmed: 7968486
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
PeerJ. 2020 Oct 16;8:e10234
pubmed: 33088633
Mol Biol Evol. 2007 Aug;24(8):1586-91
pubmed: 17483113
JAMA. 2022 Jan 25;327(4):319-320
pubmed: 34935863
Emerg Infect Dis. 2021 Feb;27(2):547-551
pubmed: 33207152
Genetics. 2012 Aug;191(4):1397-401
pubmed: 22661328
Genomics Proteomics Bioinformatics. 2022 Dec;20(6):1214-1223
pubmed: 35760317
J Infect Public Health. 2023 Jan;16(1):4-14
pubmed: 36446204
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Annu Rev Genomics Hum Genet. 2018 Aug 31;19:73-96
pubmed: 29799802
Euro Surveill. 2020 Jun;25(23):
pubmed: 32553059
Bioinformatics. 2001 Jul;17(7):660-1
pubmed: 11448887
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
Comput Appl Biosci. 1997 Oct;13(5):555-6
pubmed: 9367129
Nat Rev Genet. 2010 Jul;11(7):499-511
pubmed: 20517342
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Bioinformatics. 2003 Aug 12;19(12):1572-4
pubmed: 12912839
Mol Biol Evol. 2020 Feb 1;37(2):599-603
pubmed: 31633786